インサイダー規制拡大へ、金融庁 株式買い付け先の関係者も

【経済】インサイダー規制拡大へ、金融庁が株式買い付け先の関係者も対象に検討

2025年10月9日 19:25(19:28更新)
※この記事は有料会員限定です。

金融庁は、株式公開買い付け(TOB)に伴うインサイダー取引に関し、規制の対象を拡大する方向で検討していることが9日に判明しました。

これまで、規制対象は買収される企業側の役員に限定されていましたが、今後は株式買い付け先の関係者も対象に含める方針です。

詳細は有料会員向けの記事でご覧いただけます。7日間の無料トライアルもご用意しておりますので、この機会にぜひご利用ください。

【関連情報】
金融庁=9日午後、東京・霞が関

※クリップ機能は有料会員限定でご利用いただけます。
※西日本新聞meのサービスについて詳しくは公式サイトをご参照ください。
https://www.nishinippon.co.jp/item/1409478/

Two Edelweiss Entities Settle Alternative Investment Fund Rules Violation Case With SEBI After Paying ₹61.4 Lakh Settlement Charge

**Edelweiss Entities Settle Sebi Case Over Alleged AIF Rule Violations**

*New Delhi:* Two Edelweiss entities have reached a settlement with market regulator Sebi in a case involving alleged violations of alternative investment fund (AIF) rules. Collectively, they paid Rs 61.4 lakh towards settlement charges.

The entities involved – Edelweiss Stressed and Troubled Assets Revival Fund Trust and Edelweiss Alternative Asset Advisors Ltd – were also directed by Sebi that their officers-in-default will be barred from engaging with the company for 12 months.

“The instant adjudication proceedings initiated against the noticees, Edelweiss Stressed and Troubled Assets Revival Fund Trust and Edelweiss Alternative Asset Advisors Ltd, vide show cause notice dated July 12, 2024, are hereby disposed of,” said Sebi’s adjudicating officer Sudeep Mishra in the order dated Tuesday.

The order followed the filing of two settlement applications by the entities, proposing to settle proceedings initiated against them through the show-cause notice issued on July 12, 2024, without “admission or denial of the findings of fact and conclusions of law.”

### Background of the Case

The case originated from complaints lodged on SCORES, Sebi’s online grievance platform, alleging lapses in governance and conflict management against the Edelweiss-managed AIF.

According to the regulator, Edelweiss Stressed and Troubled Assets Revival Fund Trust failed to act in the interest of investors and did not exercise independent professional judgment, thereby violating Sebi’s norms.

Furthermore, Edelweiss Alternative Asset Advisors Ltd was found to have failed to carry out AIF activities in accordance with the Private Placement Memorandum (PPM) and submitted inaccurate information to the trustee in the compliance test report for the financial year 2016-17, constituting further violations of AIF regulations.

Following these findings, Sebi issued a show-cause notice to the entities on July 12, 2024.

### Settlement and Corrective Actions

After receiving the show-cause notice, the entities submitted revised settlement terms. These were approved by Sebi’s high-powered advisory committee, and the settlement amount was duly paid and confirmed by the regulator.

Edelweiss also informed Sebi of corrective measures undertaken, including:

– Formation of a fund board comprising independent members
– Establishment of a governance committee to monitor conflict situations
– Imposition of a one-year ban on officers-in-default from associating with the company

Sebi emphasized that the settlement is without prejudice to its right to reopen the matter should any disclosures be found false or incomplete.

*Disclaimer: This story is from a syndicated feed. No changes have been made except to the headline.*
https://www.freepressjournal.in/business/two-edelweiss-entities-settle-alternative-investment-fund-rules-violation-case-with-sebi-after-paying-614-lakh-settlement-charge

Bybit and Nexo Launch Tools to Fight $10B Scam Crisis

With nearly $10 billion lost to scams last year, major crypto platforms are stepping up efforts to protect users. Two of the biggest names, Bybit and Nexo, have each introduced new security tools aimed at mitigating the impact of fraud that continues to plague digital assets.

### Different Tactics, Same Goal

Bybit has focused on the problem of stolen funds flowing into its platform. Rather than waiting for legal action, it has created a private reporting line exclusively for its top-tier clients. This line provides direct access to the exchange’s internal security team. Cases are reviewed around the clock, and accounts can be restricted within hours to preserve evidence before involving the police.

Nexo, on the other hand, is attempting to stop scams at the point of transaction. Its upgraded Anti-Scam Engine operates quietly in the background, analyzing behavior across multiple blockchains. If suspicious activity is detected, clients are prompted to double-check before sending funds. In rare cases, the system can temporarily halt a transfer until it is reviewed.

Currently, Bybit’s reporting portal is reserved for VIP users but may expand to retail traders if testing proves successful. Nexo’s tool is already live on networks including Ethereum, Polygon, BNB Chain, and Arbitrum, with Bitcoin, Solana, Tron, and XRP slated to follow.

### Pressure to Act

Both companies acknowledge that scams are becoming increasingly sophisticated, ranging from romance schemes to pig butchering campaigns that can drag on for months. Regulators have also increased pressure on exchanges to demonstrate their ability to prevent abuse before it results in billion-dollar losses.

David Zong of Bybit stated that the company aims to move faster than law enforcement can. Meanwhile, Elitsa Taskova of Nexo emphasized that protection should feel invisible until it’s needed. Despite differing philosophies, the message is clear: crypto platforms cannot afford to leave their users exposed.

*The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.*

**About the Author**
Alex is a reporter at Coindoo with over 8 years of experience in the crypto, blockchain, and fintech industries. An experienced financial journalist and cryptocurrency enthusiast, Alex provides insightful and thought-provoking articles that break down complex topics into clear, accessible content. Follow his publications to stay updated on the latest trends and developments in digital assets.
https://coindoo.com/bybit-and-nexo-launch-tools-to-fight-10b-scam-crisis/

Doctor prescribed highly addictive painkiller from a hospital he no longer worked at

A Limerick-Based Doctor Faces Professional Misconduct Inquiry Over Prescription Incident

A doctor from Limerick has been accused of professional misconduct for using a prescription form from a hospital where he no longer worked to prescribe a high-strength, highly-addictive painkiller to a family friend.

The doctor appeared before a fitness-to-practise hearing of the Medical Council on Monday. During the hearing, he admitted the facts of certain allegations but made no admissions regarding whether these amounted to professional misconduct or poor professional performance.

### Prescription Raised Concerns

The inquiry heard that a complaint was made to the Medical Council after a pharmacist at a Boots pharmacy in Limerick became suspicious about a prescription submitted by a woman referred to as Patient A on October 6th, 2021.

The fitness-to-practise committee overseeing the inquiry ruled that the identity of the doctor cannot be made public.

### Details of the Prescription

The prescription was written on notepaper from the Department of Psychiatry at St Luke’s General Hospital in Kilkenny, dated September 29th, 2021, and signed by the doctor. The form contained a watermark stating “not for MDA drugs,” although the prescription was for a 28-day supply of OxyNorm — a strong opioid analgesic classified as a controlled drug under the Misuse of Drugs Act.

Counsel for the Medical Council, Eoghan O’Sullivan BL, explained that the pharmacist then confirmed with the hospital that the woman had never been a patient at St Luke’s, and the doctor had not worked there for approximately a year.

### Admissions and Explanation from the Doctor

Mr. O’Sullivan acknowledged that the doctor made certain admissions of fact in December 2021, including that he had written the prescription, which he accepted was inappropriate. However, the doctor claimed he prescribed the medication for special and substantial reasons, specifically to help a family friend who was in severe pain from a long-term condition, erosive esophagitis. The inquiry was told that the doctor intended the prescription to tide her over for a number of days.

### Additional Allegations

The doctor also faced two other allegations: failing to carry out an examination of Patient A and maintain adequate medical records of her treatment, as well as the unauthorized use of a HSE prescription pad.

The inquiry noted that the doctor, who qualified in 2011 and has been registered to work in Ireland since 2017, has not practised medicine since the complaint was filed. He was not suspended in relation to this case.

### Expert Witness Opinion

Fiona Fenton, a consultant psychiatrist specializing in substance misuse, gave expert evidence on behalf of the Medical Council. She stated that writing a prescription for a controlled drug when the doctor was not employed at St Luke’s, and for someone who was not his patient, constituted professional misconduct. According to Prof. Fenton, the doctor’s actions fell considerably short of the standards expected of medical professionals.

Prof. Fenton explained that the appropriate treatment for the patient’s condition was a proton pump inhibitor and antacid medication aimed at reducing stomach acid. OxyNorm, a strong opioid painkiller, is only recommended for advanced cancer or post-operative pain management and should be prescribed short-term due to its addictive nature. The psychiatrist emphasized that OxyNorm is not used in psychiatry.

She added that the proper course of action for the doctor, when asked for pain relief, should have been to refer Patient A to an on-call doctor service or the emergency department of a local hospital. Prof. Fenton also noted that suitable medication for the patient’s condition could have been obtained over the counter at pharmacies or even supermarkets.

While she considered the doctor’s actions amounted to poor professional performance, she did not believe they met the legal threshold for such a finding, as there was no adverse outcome for the patient.

### Legal Representation and Outcome

David Higgins, the doctor’s solicitor, said his client was genuinely remorseful and had learned from the incident. Mr. Higgins described the event as a one-off incident, admitted at an early stage, with no personal gain for the doctor. He characterized it as an isolated error made under stressful circumstances while assisting a family friend experiencing chronic pain.

The fitness-to-practise committee made no findings against the doctor after accepting his offer of an undertaking regarding future conduct. Additionally, the doctor agreed to complete a continuous professional development course on prescribing before resuming medical practice and consented to be censured.

*This case highlights the importance of adhering to proper medical protocols when prescribing controlled substances and the consequences of unauthorized use of medical resources.*
https://www.breakingnews.ie/ireland/doctor-prescribed-highly-addictive-painkiller-from-a-hospital-he-no-longer-worked-at-1812652.html

Which Adani stock should you buy following SEBI’s clean chit?

**Which Adani Stock Should You Buy Following SEBI’s Clean Chit?**
*By Dwaipayan Roy | Sep 28, 2025, 04:48 PM*

Adani Group stocks have been in the spotlight recently after the Securities and Exchange Board of India (SEBI) cleared all allegations raised by Hindenburg Research back in January 2023. This significant development has bolstered investor confidence, sparking a relief rally that has outperformed the broader market.

On September 22, SEBI gave a clean chit to Adani Ports & Special Economic Zone Ltd and Adani Power Ltd, confirming that these companies did not breach any regulations as claimed by the US-based short-seller Hindenburg. This clearance has reignited interest in Adani Group stocks among investors and analysts alike.

### Investment Advice: Focus on Adani Green

Following SEBI’s clean chit, analysts recommend keeping an eye on **Adani Green** stock. Shiju Kuthupalakkal from Prabhudas Lilladher noted that, from a technical standpoint, Adani Green appears well positioned. The stock recently witnessed a breakout, suggesting potential upside.

Kuthupalakkal expects some consolidation followed by a pullback that could improve the overall bias. He highlighted near-term target prices of ₹1,220, with further strength possibly pushing the stock up to ₹1,360.

### Market Performance Insights from Choice Broking

Hardik Matalia of Choice Broking also sees promising potential in Adani Green shares. The stock is currently trading around ₹1,047 after experiencing a sharp decline of nearly 65% from its swing high.

Despite this significant correction, Adani Green entered a prolonged consolidation phase. Recently, the stock has demonstrated renewed strength, bouncing strongly from its support zones, indicating potential for further gains.

### Conclusion

With SEBI’s clearance alleviating regulatory concerns, Adani Green emerges as a compelling pick among Adani Group stocks. Investors looking for opportunities within the group may consider monitoring Adani Green closely as it shows signs of technical improvement and market resilience.
https://www.newsbytesapp.com/news/business/adani-group-stocks-in-focus-what-analysts-recommend/story

Doctor accused of professional misconduct over Covid-19 criticism alleges collusion

A Dublin-based GP accused of professional misconduct for criticising Covid-19 measures and restrictions on social media has claimed there has been a degree of collusion to frame evidence against him at a medical inquiry.

Marcus de Brun called for the evidence of an expert witness, Colin Bradley, who had concluded that the GP’s actions were disgraceful and dishonourable, to be excluded from the case against him.

### Dispute Over Expert Witness Evidence

The application to exclude Prof Bradley’s evidence arose after Dr de Brun claimed that the expert witness’s concerns about a viral immunologist, Graham Bottley, who had made a complaint about the GP to the Medical Council, were not referenced in a report Prof Bradley provided to a committee recommending a fitness-to-practise inquiry.

Dr de Brun further alleged that plans by the Medical Council to call Dr Bottley as a witness were only abandoned earlier in the week after he objected. He also argued that Prof Bradley’s evidence should be excluded because the expert witness was asked by the regulatory body’s Preliminary Proceedings Committee to provide an additional report addressing the seriousness of the GP’s actions.

Dr de Brun told the fourth day of the inquiry before a Fitness-to-Practice Committee of the Medical Council that admitting Prof Bradley’s evidence would be unfair, as it lacks independence.

### Allegations Against Dr de Brun

The father of four, who operated his own practice in Rush, Co Dublin, faces ten counts of professional misconduct over his criticism of public health guidelines, lockdowns, facemask mandates, and Covid-19 vaccines during the pandemic.

Allegations also relate to comments he made at a public rally in Dublin in August 2020, where he was accused of failing to wear a facemask and observe social distancing.

The Medical Council claims Dr de Brun’s comments and actions were inappropriate, undermined public health guidelines, and contravened sections of the Guide to Professional Conduct and Ethics.

### Dr de Brun’s Defence

However, the GP maintains that the deaths of his patients in a nursing home during the pandemic—and the subsequent anger and upset he expressed on Twitter—were consequences of Government guidelines and the Medical Council’s inaction.

Dr de Brun resigned from the Medical Council in April 2020 over what he described as the State’s failure to protect nursing home residents.

It emerged that Dr Bottley made a complaint against Dr de Brun to the regulatory body in January 2021, after a Twitter dispute between the two.

### Expert Witness Prof Bradley’s Position

The inquiry heard that Prof Bradley cautioned the Medical Council in an email in August 2023 against relying on Dr Bottley’s social media posts to challenge Dr de Brun’s views, noting Dr Bottley’s standing was controversial.

Under cross-examination by Dr de Brun, who is representing himself, Prof Bradley accepted he had not referenced his concerns about Dr Bottley in any report to the Medical Council.

Prof Bradley described Dr Bottley as a controversial figure presenting himself as a virologist and stated it was particularly inappropriate for a medical practitioner to engage in online discussions that encouraged vaccine hesitancy, such as those by Dr de Brun.

He said he relied on the views of bodies like the National Immunisation Advisory Committee when assessing whether the GP’s conduct constituted serious failures, rather than on the Twitter dispute.

Prof Bradley told the inquiry he believed the doctor had crossed the line into serious misuse of social media by discouraging compliance with public health guidelines during a serious pandemic.

While admitting it was his fault that he had not addressed the seriousness of Dr de Brun’s conduct in his initial report, Prof Bradley rejected any suggestion that he was directed on what to include in his reports.

### Medical Council’s Position

Counsel for the Medical Council, Neasa Bird BL, said that requesting Prof Bradley to provide an additional report did not undermine his independence as an expert witness.

Ms Bird rejected Dr de Brun’s assertion that the Medical Council had coached or influenced how Prof Bradley presented his evidence, maintaining that nothing claimed by the GP undermined the witness’s independence, credibility, or reliability.

### Cross-Examination Highlights

Under cross-examination, Dr de Brun told Prof Bradley that claims he was dismissive towards patients were emotive, highlighting his 23 years of unblemished practice as a GP.

“I consider myself to have a very, very good and very empathetic and caring relationship with my patients,” he said.

Dr de Brun read an email from a patient who said they would be “greatly saddened” if their social media interactions with the doctor were taken out of context. The patient stated they had never taken offence at anything Dr de Brun had said publicly or privately, including on social media.

Prof Bradley responded that his concern was that while the GP’s tweet might have been directed at someone he knew, it could be interpreted by others as dismissive of their condition.

“I felt it was very open to interpretation that you were being dismissive of patients with diabetes or long Covid,” said Prof Bradley. “Once it’s on Twitter, it’s a comment that’s open to everyone to read and be affected by it.”

### Additional Remarks

The inquiry heard that Prof Bradley noted some of Dr de Brun’s statements were supported by other doctors and commentators who present critiques of government Covid-19 policy more reasonably.

The inquiry’s chairperson, Deirdre Murphy, adjourned the hearing and said the committee would deliver its ruling on the application to dismiss Prof Bradley’s evidence at a future date.
https://www.breakingnews.ie/ireland/doctor-accused-of-professional-misconduct-over-covid-19-criticism-alleges-collusion-1811564.html

$300B Wiped From Crypto Markets in Days as BTC Tanks Below $110K After Powell Speech: Your Weekly Recap

It wasn’t a particularly good week for Bitcoin and the broader crypto market, as almost all charts are deep in the red on a 7-day scale.

The downturn began at the end of the previous business week after BTC jumped to $118,000 on Thursday morning following the Fed’s expected rate cut. However, the asset’s rally ran its course prematurely, and it started to lose value gradually, dropping to $116,000 by Friday.

The weekend unfolded as anticipated, with little to no action. Then came the familiar Monday drop. Bitcoin went from just over $115,500 to $112,000, wiping out billions of dollars worth of leveraged positions. The bulls tried to halt the freefall, briefly pushing BTC to $114,000 on Tuesday. However, the bears quickly reemerged and initiated another couple of consecutive leg downs.

The culmination took place earlier on Friday when BTC plunged to $108,600 — its lowest price tag since the start of the month. Perhaps the most evident reason behind this collapse is the latest comments from US Fed Chair Jerome Powell. The head of the central bank sent mixed signals regarding inflation levels, which were interpreted as a warning sign for riskier assets like crypto.

Although BTC has recovered some ground since its local low, it is still beneath $110,000 as of press time. Its 6.2% weekly decline, however, seems negligible compared to massive double-digit drops from the likes of ETH, DOGE, SOL, ADA, LINK, AVAX, and especially HYPE, which is down by over 25% following the rise of a new competitor — more on that later.

These price collapses are best highlighted by the total market cap’s plunge, which fell from over $4.150 trillion last Friday to under $3.850 trillion as of now.

**Market Data**
– Market Cap: $3.840T
– 24H Volume: $238B
– BTC Dominance: 56.8%

**Cryptocurrency Prices**
– BTC: $109,200 (-6.2%)
– ETH: $3,920 (-13%)
– XRP: $2.75 (-9%)

### This Week’s Crypto Headlines You Can’t Miss

**Tether Seeks $20B Funding at $500 Billion Valuation, Dwarfing Circle**
The company behind the world’s largest stablecoin reaffirmed its dominance in the crypto market by securing somewhere between $15 and $20 billion for a 3% stake, according to a recent report. This implies a valuation of roughly $500 billion—far surpassing its closest rival, Circle, which is valued at $30 billion.

**Fear and Greed Index Hits 5-Month Low as BTC Drops to $109K: Warning or Buying Opportunity?**
After losing roughly $10,000 since last Thursday’s peak, market sentiment has understandably turned grim. The popular Fear and Greed Index plunged to its lowest level in roughly five months as a result.

**SBF’s ‘gm’ Tweet Sparks Speculation of Comeback Amidst New Solana-Based Perp DEX**
FTX’s notorious former leader made a simple but loud return to social media this week by posting a minor “gm” message on X. The tweet had a dramatic impact on FTT’s price and led to speculation about a new Solana-based perpetual decentralized exchange (DEX).

**The Bitcoin Bear Market Is Here: Hyperliquid’s Competitor Surpasses It in Volume**
The meteoric rise of ASTER and its native token has helped one whale turn a $300,000 investment into a $7 million fortune in just weeks, marking a significant shift in market dynamics.

**Analysts Predict Massive “Uptober” Rally Despite This Week’s Market Rout**
Ending on a hopeful note, several crypto analysts have outlined bullish projections for October (often referred to as “Uptober”), including predictions of a price surge to new all-time highs.

### Charts
This week, we feature an in-depth chart analysis of Ethereum, Ripple, Cardano, Binance Coin, and Hyperliquid. [Click here for the complete price analysis.](#)

Stay tuned for more updates as the crypto market continues to evolve.
https://bitcoinethereumnews.com/bitcoin/300b-wiped-from-crypto-markets-in-days-as-btc-tanks-below-110k-after-powell-speech-your-weekly-recap/?utm_source=rss&utm_medium=rss&utm_campaign=300b-wiped-from-crypto-markets-in-days-as-btc-tanks-below-110k-after-powell-speech-your-weekly-recap

XRP ETF hype surges – Yet THESE on-chain metrics signal caution!

**Does XRP’s ETF Optimism Guarantee a Sustained Rally?**

While optimism surrounding XRP’s potential ETF approval may provide temporary relief, it does not guarantee a sustained rally. Weak network growth and negative address activity divergence continue to limit lasting bullish momentum for the cryptocurrency.

### What Are Recent Open Interest and On-Chain Metrics Indicating About XRP?

Recent data shows a decline in Open Interest (OI) along with subdued on-chain activity, indicating a cautious stance among traders. This hesitance reflects insufficient speculative support to drive a strong and sustainable rally in XRP’s price.

### Evolving XRP Spot ETF Landscape

The XRP spot ETF scene is rapidly developing. Franklin Templeton’s filing has been extended into November, signaling ongoing regulatory processes. Meanwhile, the REX-Osprey XRPR ETF, which launched on September 18th, recorded an impressive $37.7 million in trading volume on its first day—making it one of the largest ETF debuts of the year.

Despite this positive news, the Spot Taker Cumulative Volume Delta (90-day) continues to show sellers dominating the market. This suggests that profit-taking and heavy sell pressure remain entrenched. Although there were intermittent bursts of buyer strength during the summer, sellers quickly regained control, leaving momentum biased against bulls. This imbalance underscores the short-term risks XRP faces, where ETF optimism must contend with a market struggling to generate decisive buyer inflows and break sustained downward pressure.

### Network Growth and Transaction Activity Fall Short

On-chain signals remain muted. XRP’s network growth has slid to just 4,849 active addresses, while transaction counts hover around 617,000—both figures are near their recent lows. These metrics point to muted adoption and weaker user engagement.

Historically, subdued network activity has limited XRP’s ability to sustain price rallies, even amid broader market optimism. While ETF approval may offer temporary price boosts, structural growth depends on consistent network expansion and higher transaction volumes. Without meaningful new participants joining the ecosystem, underlying weaknesses threaten to dampen bullish momentum despite favorable regulatory catalysts.

### Is Declining Address Activity a Warning Sign?

Daily Active Addresses (DAA) divergence further highlights XRP’s fragile momentum. Participation metrics have been lagging behind price action, signaling weakening organic growth.

The persistent negative DAA divergence suggests traders remain hesitant to stay engaged, as network adoption fails to gain traction. In such an environment, rallies often struggle to sustain because price increases aren’t supported by a growing base of active users. As activity stagnates, XRP risks losing alignment between demand and valuation, making ETF-driven optimism appear more speculative than fundamentally supported. This address divergence continues to cast doubt on XRP’s ability to build lasting bullish traction.

### Open Interest Slides as Traders Reduce Exposure

Open Interest in XRP derivatives dropped by 3.34%, settling around $7.33 billion. This decline highlights reduced speculative positioning across futures markets, signaling that traders are exercising caution rather than conviction.

While lower exposure may help reduce short-term volatility, it also indicates waning appetite for risk-taking and less leverage supporting potential rallies. Historically, significant XRP uptrends have aligned with rising Open Interest, underscoring the importance of derivative market activity. Current trends, however, point toward fading speculative strength even as ETF anticipation grows.

### Can ETF Optimism Offset On-Chain Weakness?

Despite increasing speculation around XRP’s ETF approval, several headwinds remain dominant: seller pressure, subdued network activity, negative address divergence, and declining Open Interest.

For XRP to mount a sustainable rally, investor enthusiasm must be matched by stronger on-chain growth rather than relying solely on regulatory developments. Although ETF approval could spark temporary price relief, without renewed activity across the network and derivatives markets, upside momentum risks quickly fading.

The evidence suggests XRP requires deeper structural participation and broader ecosystem engagement before ETF optimism can translate into lasting gains.

**In summary, while XRP’s ETF prospects provide a promising catalyst, fundamental challenges in network growth and trader engagement underscore the risks of expecting a sustained rally based solely on regulatory optimism.**
https://ambcrypto.com/xrp-etf-hype-surges-yet-these-on-chain-metrics-signal-caution/

Mumbai: NGT-Ordered Committee Finds Ashapura Meinchem Limited Guilty Of Severe Environmental Violations In Ratnagiri, Recommends Crores In Fines

**Mumbai: National Green Tribunal Committee Highlights Severe Environmental Violations by Ashapura Meinchem Ltd. in Ratnagiri**

A committee constituted under the orders of the National Green Tribunal (NGT) has released a report exposing major environmental violations committed by Ashapura Meinchem Ltd., a mining company operating in Rowle village, Ratnagiri. The investigation was initiated following a complaint lodged by Bhavesh Karekar, an engineer-turned-agriculturalist, who accused the company of illegal bauxite mining and causing significant environmental degradation in the area.

### Complaint Details

Bhavesh Karekar raised serious concerns about the company’s unregulated excavation activities, including:

– Illegal mining operations without the required permissions or No Objection Certificates (NOCs)
– Haphazard mining and crushing activities leading to severe environmental damage
– Depletion and contamination of groundwater resources in surrounding areas
– Uncontrolled air pollution due to mining without proper air quality monitoring
– Failure to conduct mandated plantation drives in the affected zones
– Damage to public roads caused by overloading of transport vehicles
– Significant structural damage to a public bridge over the Barja River, a critical evacuation route for mined materials
– Night-time mining operations, violating existing regulations

### Committee Findings

The committee’s report corroborated many of Karekar’s allegations and found that Ashapura Meinchem Ltd. had obtained Environmental Clearance (EC) based solely on subsurface mining rights for 228 hectares. However, the company did not hold agreements for surface rights over all the land involved.

Additionally, the report noted the company’s failure to adhere to conditions related to:

– Tree plantation requirements
– Mineral transportation protocols
– Operation of stone crushers without acquiring necessary consents from the Maharashtra Pollution Control Board (MPCB)

### Concerns Regarding Infrastructure

The investigation also raised alarms about the Barja River bridge, which currently shows visible cracks and has limited load-bearing capacity. The committee recommended that the Public Works Department (PWD) and Regional Transport Office (RTO) conduct a thorough safety audit of the bridge. Until the audit is completed, the transportation of minerals via this bridge should be suspended to prevent further damage or potential accidents.

### Recommended Actions

The committee suggested strict punitive measures against Ashapura Meinchem Ltd. for non-compliance, including:

– Installation of CCTV cameras to closely monitor mining activities
– Maintenance and repair of public roads at the company’s expense, following the Polluter Pays Principle

### Environmental Compensation

Based on its findings, the committee recommended imposing substantial environmental compensation fees on the company, including:

– Rs. 1,74,60,000 for violations related to environmental regulations, such as insufficient tree plantation and illegal mining operations
– Rs. 26,73,600 for unauthorized groundwater extraction without obtaining the necessary NOC from the Central Ground Water Authority (CGWA)

This report underscores the urgent need for stricter regulatory oversight and stringent enforcement of environmental laws to curb illegal mining activities and protect the fragile ecosystem of Ratnagiri.
https://www.freepressjournal.in/mumbai/mumbai-ngt-ordered-committee-finds-ashapura-meinchem-limited-guilty-of-severe-environmental-violations-in-ratnagiri-recommends-crores-in-fines